Works matching AU Bosch, F.


Results: 337
    1
    2

    Causes of cervical cancer in the Philippines: a case-control study.

    Published in:
    1998
    By:
    • Ngelangel, Cora;
    • Munoz, Nubia;
    • Bosch, F. Xavier;
    • Limson, Genara M.;
    • Festin, Mario R.;
    • Deacon, Judith;
    • Jacobs, Marcel V.;
    • Santamaria, Mercedes;
    • Meijer, Chris J.L.M.;
    • Walboomers, Jan M.M.;
    • Ngelangel, C;
    • Muñoz, N;
    • Bosch, F X;
    • Limson, G M;
    • Festin, M R;
    • Deacon, J;
    • Jacobs, M V;
    • Santamaria, M;
    • Meijer, C J;
    • Walboomers, J M
    Publication type:
    journal article
    3

    Risk factors for cervical cancer in Thailand: a case-control study.

    Published in:
    1998
    By:
    • Chichareon, Saibua;
    • Herrero, Rolando;
    • Munoz, Nubia;
    • Bosch, F. Xavier;
    • Jacobs, Marcel V.;
    • Deacon, Judith;
    • Santamaria, Mercedes;
    • Chongsuvivatwong, Virasakdi;
    • Meijer, Chris J.L.M.;
    • Walboomers, Jan M.M.;
    • Chichareon, S;
    • Herrero, R;
    • Muñoz, N;
    • Bosch, F X;
    • Jacobs, M V;
    • Deacon, J;
    • Santamaria, M;
    • Chongsuvivatwong, V;
    • Meijer, C J;
    • Walboomers, J M
    Publication type:
    journal article
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13

    Serological response to HPV16 in CIN-III and cervical-cancer patients. Case-control studies in Spain and Colombia.

    Published in:
    International Journal of Cancer, 1996, v. 66, n. 1, p. 70, doi. 10.1002/(SICI)1097-0215(19960328)66:1<70::AID-IJC13>3.0.CO;2-F
    By:
    • De Sanjosé, Silvia;
    • Hamsikova, Eva;
    • Muñoz, Nubia;
    • Xavier Bosch, F.;
    • Hofmannová, Vanda;
    • Gili, Miguel;
    • Izarzugaza, Isabel;
    • Viladiu, Pau;
    • Tormo, María José;
    • Moreo, Pilar;
    • Munoz, María Teresa;
    • Ascunce, Nieves;
    • Tafur, Luis;
    • Shah, Keerti V.;
    • Vonka, Vladimir
    Publication type:
    Article
    14

    Cervical cancer and herpes simplex virus type 2: Case-control studies in Spain and Colombia, with special reference to immunoglobulin-G sub-classes.

    Published in:
    International Journal of Cancer, 1995, v. 60, n. 4, p. 438, doi. 10.1002/ijc.2910600403
    By:
    • Muñoz, Nubia;
    • Kato, Ikuko;
    • Bosch, F. Xavier;
    • De Sanjosé, Silvia;
    • Sundquist, Vivi-Anne;
    • Izarzugaza, Isabel;
    • Gonzalez, Luis Carlos;
    • Tafur, Luis;
    • Gili, Miguel;
    • Viladiu, Pablo;
    • Navarro, Carmen;
    • Moreo, Pilar;
    • Guerrero, Eloisa;
    • Shah, Keerti V.;
    • Wahren, Britta
    Publication type:
    Article
    15

    Sexually transmitted agents and cervical neoplasia in colombia and Spain.

    Published in:
    International Journal of Cancer, 1994, v. 56, n. 3, p. 358, doi. 10.1002/ijc.2910560311
    By:
    • de Sanjosé, S.;
    • Muñoz, N.;
    • Bosch, F. X.;
    • Reimann, K.;
    • Pedersen, N. S.;
    • Orfila, J.;
    • Ascunce, N.;
    • González, L. C.;
    • Tafur, L.;
    • Gili, M.;
    • Lette, I.;
    • Viladiu, P.;
    • Tormo, M. J.;
    • Moreo, P.;
    • Shah, K.;
    • Wahren, B.
    Publication type:
    Article
    16
    17
    18
    19

    Risk factors for cervical cancer in Colombia and Spain.

    Published in:
    International Journal of Cancer, 1992, v. 52, n. 5, p. 750, doi. 10.1002/ijc.2910520514
    By:
    • Bosch, F. X.;
    • Muñoz, N.;
    • de Sanjosé, S.;
    • Izarzugaza, I.;
    • Gili, M.;
    • Viladiu, P.;
    • Tormo, M. J.;
    • Moreo, P.;
    • Ascunce, N.;
    • Gonzalez, L. C.;
    • Tafur, L.;
    • Kaldor, J. M.;
    • Guerrero, E.;
    • Aristizabal, N.;
    • Santamaria, M.;
    • De Ruiz, P. Alonso;
    • Shah, K.
    Publication type:
    Article
    20
    21
    22
    23
    24
    25

    Buffering and bridging as environmental strategies of firms.

    Published in:
    Business Strategy & the Environment (John Wiley & Sons, Inc), 1998, v. 7, n. 1, p. 24, doi. 10.1002/(SICI)1099-0836(199802)7:1<24::AID-BSE130>3.0.CO;2-I
    By:
    • van den Bosch, F. A. J.;
    • van Riel, C. B. M.
    Publication type:
    Article
    26
    27
    28

    Long-Term Experience with Subcutaneous ICD Leads:.

    Published in:
    Pacing & Clinical Electrophysiology, 2004, v. 27, n. 10, p. 1355, doi. 10.1111/j.1540-8159.2004.00639.x
    By:
    • KETTERING, KLAUS;
    • MEWIS, CHRISTIAN;
    • DÖRNBERGER, VOLKER;
    • VONTHEIN, REINHARD;
    • BOSCH, RALPH F.;
    • SEIPEL, LUDGER;
    • KÜHLKAMP, VOLKER
    Publication type:
    Article
    29
    30
    31
    32
    33

    A Novel Human Papillomavirus Sequence From An International Cervical Cancer Study.

    Published in:
    Journal of Infectious Diseases, 1994, v. 170, n. 5, p. 1093, doi. 10.1093/infdis/170.5.1093
    By:
    • Peyton, Cheri L.;
    • Jansen, Angela M.;
    • Wheeler, Cosette M.;
    • Stewart, Ann-Charlotte;
    • Peto, Julian;
    • Bosch, F. Xavier;
    • MuñOz, Nubia;
    • Teyssie, Angelica R.;
    • Torroella, Marta;
    • Wabinga, Henry R.;
    • Sarjadi;
    • Ngelangel, Corazon;
    • Manos, M. Michele
    Publication type:
    Article
    34
    35

    GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RESPONSES AND A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA.

    Published in:
    Hematological Oncology, 2023, v. 41, p. 138, doi. 10.1002/hon.3163_92
    By:
    • Hutchings, M.;
    • Avigdor, A.;
    • Sureda, A.;
    • Terol, M. J.;
    • Bosch, F.;
    • Corradini, P.;
    • Larsen, T. Stauffer;
    • Domínguez, A. Rueda;
    • Skarbnik, A.;
    • Jørgensen, J.;
    • Goldschmidt, N.;
    • Gurion, R.;
    • Zinzani, P. L.;
    • Pinto, A.;
    • Cordoba, R.;
    • Bottos, A.;
    • Huang, Z.;
    • Simko, S.;
    • Relf, J.;
    • Filézac de L'Etang, A.
    Publication type:
    Article
    36

    COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE AND SHOWS EARLY EFFICACY IN PATIENTS SUFFERING FROM RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA.

    Published in:
    Hematological Oncology, 2023, v. 41, p. 136, doi. 10.1002/hon.3163_91
    By:
    • Hutchings, M.;
    • Dickinson, M.;
    • Carlo‐Stella, C.;
    • Morschhauser, F.;
    • Bosch, F.;
    • Gritti, G.;
    • Townsend, W.;
    • Bartlett, N. L.;
    • Cartron, G.;
    • Ghesquieres, H.;
    • Houot, R.;
    • Walter, H.;
    • Offner, F.;
    • Christiansen, A.;
    • Dimier, N.;
    • Jamois, C.;
    • Harrop, E.;
    • Herter, S.;
    • Hölzlwimmer, G.;
    • Keelara, A.
    Publication type:
    Article
    37
    38

    Phase 1 trial of EO2463 peptide‐based immunotherapy as monotherapy and in combination with lenalidomide and rituximab in indolent non‐Hodgkin lymphoma; EONHL1‐20/SIDNEY.

    Published in:
    Hematological Oncology, 2023, v. 41, p. 581, doi. 10.1002/hon.3164_435
    By:
    • Pinto, A. A.;
    • Bosch, F.;
    • Bisneto, J. C. Villasboas;
    • Sanz, R. García;
    • Garcia, C. Grande;
    • Smith, S. D.;
    • Wallace, D. S.;
    • Arcaini, L.;
    • Merryman, R.;
    • Marolleau, J.;
    • De Filippi, R.;
    • Chêne, L.;
    • Bonny, C.;
    • Fagerberg, J.;
    • Friedberg, J. W.;
    • Ansel, S.;
    • Armand, P.;
    • Zinzani, P. L.
    Publication type:
    Article
    39
    40

    ANTITUMORAL ACTIVITY OF THE NOVEL BTK INHIBITOR TG‐1701 IS ASSOCIATED WITH DISRUPTION OF IKAROS SIGNALING AND IMPROVEMENT OF ANTI‐CD20 THERAPY IN B‐CELL NON‐HODGKIN LYMPHOMA.

    Published in:
    Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.153_2880
    By:
    • Ribeiro, M. L;
    • Reyes‐Garau, D;
    • Vinyoles, M;
    • Profitos‐Peleja, N;
    • Santos, J. C;
    • Armengol, M;
    • Fernandez‐Serrano, M;
    • Bech‐Serra, J. J;
    • Blecua, P;
    • Musulen, E;
    • De la Torre, C;
    • Miskin, H;
    • Esteller, M;
    • Bosch, F;
    • Menendez, P;
    • Normant, E;
    • Roue, G
    Publication type:
    Article
    41

    THE LANDSCAPE OF DRUG PERTURBATION EFFECTS IN LEUKEMIA AND LYMPHOMA.

    Published in:
    Hematological Oncology, 2019, v. 37, p. 127, doi. 10.1002/hon.87_2629
    By:
    • Scheinost, S.;
    • Lu, J.;
    • Wagner, L.;
    • Huellein, J.;
    • Walther, T.;
    • Sellner, L.;
    • Theocharides, A.;
    • Bornhäuser, B.;
    • Kühn, M.;
    • Kindler, T.;
    • Florence Nguyen‐Khac, F.;
    • Crespo Maull, M.;
    • Bosch, F.;
    • Manz, M.;
    • Bourquin, J.;
    • Dietrich, S.;
    • Huber, W.;
    • Zenz, T.
    Publication type:
    Article
    42
    43
    44
    45
    46
    47

    MANAGING CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY WITH STEP‐UP DOSING OF MOSUNETUZUMAB IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (NHL).

    Published in:
    Hematological Oncology, 2019, v. 37, p. 310, doi. 10.1002/hon.119_2630
    By:
    • Sehn, L.H.;
    • Assouline, S.;
    • Bartlett, N.L.;
    • Bosch, F.;
    • Diefenbach, C.M.;
    • Flinn, I.;
    • Hong, J.Y.;
    • Kim, W.S.;
    • Matasar, M.;
    • Nastoupil, L.;
    • Schuster, S.J.;
    • Shadman, M.;
    • Yoon, S.S.;
    • Bender, B.;
    • Chu, W.;
    • Hernandez, G.M.;
    • Kwan, A.;
    • McCall, B.;
    • Sison, I.;
    • Wang, C.
    Publication type:
    Article
    48

    THE LANDSCAPE OF DRUG PERTURBATION EFFECTS IN LEUKEMIA AND LYMPHOMA.

    Published in:
    Hematological Oncology, 2019, v. 37, p. 127, doi. 10.1002/hon.87_2629
    By:
    • Scheinost, S.;
    • Lu, J.;
    • Wagner, L.;
    • Huellein, J.;
    • Walther, T.;
    • Sellner, L.;
    • Theocharides, A.;
    • Bornhäuser, B.;
    • Kühn, M.;
    • Kindler, T.;
    • Florence Nguyen‐Khac, F.;
    • Crespo Maull, M.;
    • Bosch, F.;
    • Manz, M.;
    • Bourquin, J.;
    • Dietrich, S.;
    • Huber, W.;
    • Zenz, T.
    Publication type:
    Article
    49
    50